4-氯-5-甲基噻吩并[2,3-d]嘧啶 | 43088-67-1

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 中文名称: 4-氯-5-甲基噻吩并[2,3-d]嘧啶
• 中文别名: 4-氯-5-甲基噻吩基[2,3-d!嘧啶；4-氯-5-甲基噻促退并[2,3-d]嘧啶
• 英文名称: 4-chloro-5-methylthieno[2,3-d]pyrimidine
• CAS: 43088-67-1
• 化学式: C₇H₅ClN₂S
• mdl: MFCD00205201
• 分子量: 184.649
• InChiKey: UAIXPCWTEUFSNI-UHFFFAOYSA-N

物化性质

• 熔点：
  137 °C
• 沸点：
  301.3±37.0 °C(Predicted)
• 密度：
  1.445±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 安全说明：
  S22,S26,S36/37/39,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 危险品标志：
  Xi
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存储条件为2-8°C，并需保存在惰性气体中。

SDS

Name:	4-Chloro-5-methylthieno[2 3-d]pyrimidine 97% Material Safety Data Sheet
Synonym:
CAS:	43088-67-1

Section 1 - Chemical Product MSDS Name:4-Chloro-5-methylthieno[2 3-d]pyrimidine 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
43088-67-1	4-Chloro-5-methylthieno[2,3-d]pyrimidi	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 43088-67-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 138 - 140 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H5ClN2S
Molecular Weight: 185

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 43088-67-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Chloro-5-methylthieno[2,3-d]pyrimidine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 43088-67-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 43088-67-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 43088-67-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯-5-甲基噻吩并[2,3-d]嘧啶 在 肼 作用下， 反应 2.0h， 生成 9-Methyl-s-triazolo<1,2-c>thieno<3,2-e>pyrimidin
  参考文献：
  名称：

  Robba,M. et al., Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques, 1968, vol. 266, p. 1706 - 1708

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨基-4-甲基-噻吩-3-羧酸乙酯 在 N,N-二甲基苯胺 、 三氯氧磷 作用下， 反应 3.0h， 生成 4-氯-5-甲基噻吩并[2,3-d]嘧啶
  参考文献：
  名称：

  AcOH介导的CC键形成反应超声辅助合成4-(1H-吲哚-3-基)噻吩并[2,3-d]嘧啶衍生物

  摘要：

  通过4-氯噻吩并[2,3- d ]嘧啶与吲哚范围。该反应使用AcOH作为促进剂以及溶剂进行，以良好到可接受的收率得到相应的产物。这种无金属方法通过CC键形成反应进行，具有条件简单、持续时间短、使用环保能源等优点。除了其缺点之外，还通过合成的化合物的药用价值展示并举例说明了该方法的有用性。化合物3i和3j在体外表现出良好的TNF-α抑制作用，被确定为初始命中分子。

  DOI：

  10.1016/j.tetlet.2023.154784

文献信息

• Thieno-pyrimidine compounds having fungicidal activity
  申请人：Brewster Kirkland William

  公开号：US20070093498A1

  公开（公告）日：2007-04-26

  The present invention relates to thieno[2,3-d]-pyrimidine compounds having fungicidal activity.

  本发明涉及具有杀真菌活性的噻吩[2,3-d]-嘧啶化合物。
• AlCl3-induced (hetero)arylation of thienopyrimidine ring: a new synthesis of 4-substituted thieno[2,3-d]pyrimidines
  作者：K. Shiva Kumar、Srinivas Chamakuri、Peddy Vishweshwar、Javed Iqbal、Manojit Pal

  DOI：10.1016/j.tetlet.2010.04.057

  日期：2010.6

  AlCl3 facilitated C–C bond forming reaction between 4-chloro-thieno[2,3-d]pyrimidines and (hetero)arenes affording a direct and single-step method for the synthesis of 4-(hetero)aryl substituted thieno[2,3-d]pyrimidines. A number of novel thienopyrimidines were prepared in good to excellent yields using this methodology. The molecular structure of a representative compound was established unambiguously

  AlCl 3促进4-氯-噻吩并[2,3- d ]嘧啶与（杂）芳烃之间的CC键形成反应，为合成4-（杂）芳基取代的噻吩并[2]提供了直接而又一步的方法。 ，3- d ]嘧啶。使用这种方法可以制备许多新颖的噻吩并嘧啶，收率良好。通过单晶X射线衍射明确地建立了代表性化合物的分子结构。
• FLAP MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20140221310A1

  公开（公告）日：2014-08-07

  The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R 1 , L and R 2 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

  本发明涉及式（I）化合物，或其形式，其中环A，R1，L和R2如本文所定义，作为FLAP调节剂有用。该发明还涉及包含式（I）化合物的药物组合物。制备和使用式（I）化合物的方法也属于本发明的范围。
• Pharmacophore Mapping of Thienopyrimidine-Based Monophosphonate (ThP-MP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase
  作者：Jaeok Park、Chun Yuen Leung、Alexios N. Matralis、Cyrus M. Lacbay、Michail Tsakos、Guillermo Fernandez De Troconiz、Albert M. Berghuis、Youla S. Tsantrizos

  DOI：10.1021/acs.jmedchem.6b01888

  日期：2017.3.9

  Recent drug discovery efforts have focused primarily on allosteric inhibition of hFPPS and the discovery of non-bisphosphonate drugs for potentially treating nonskeletal diseases. Hit-to-lead optimization of a new series of thienopyrimidine-based monosphosphonates (ThP-MPs) led to the identification of analogs with nanomolar potency in inhibiting hFPPS. Their interactions with the allosteric pocket of

  人法呢基焦磷酸合酶（hFPPS）是甲羟戊酸途径中的关键调节酶，催化C-15异戊二烯类法呢基焦磷酸（FPP）的生物合成。FPP在执行大量细胞功能的小GTP酶的翻译后异戊烯化中起关键作用。尽管hFPPS是溶骨性疾病的公认治疗靶标，但目前可用的双膦酸酯类药物表现出不良的细胞摄取能力，并分布到非骨骼组织中。最近的药物发现工作主要集中在hFPPS的变构抑制和发现潜在用于治疗非骨骼疾病的非双膦酸酯药物上。一系列基于硫代嘧啶的单膦酸酯（ThP-MPS）的先导性优化导致鉴定出具有纳摩尔浓度抑制hFPPS的类似物。它们与酶的变构口袋的相互作用通过晶体学表征，并且结果提供了对变构抑制的药效团要求的进一步见解。
• Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88^L265P Diffuse Large B-Cell Lymphoma
  作者：James S. Scott、Sébastien L. Degorce、Rana Anjum、Janet Culshaw、Robert D. M. Davies、Nichola L. Davies、Keith S. Dillman、James E. Dowling、Lisa Drew、Andrew D. Ferguson、Sam D. Groombridge、Christopher T. Halsall、Julian A. Hudson、Scott Lamont、Nicola A. Lindsay、Stacey K. Marden、Michele F. Mayo、J. Elizabeth Pease、David R. Perkins、Jennifer H. Pink、Graeme R. Robb、Alan Rosen、Minhui Shen、Claire McWhirter、Dedong Wu

  DOI：10.1021/acs.jmedchem.7b01290

  日期：2017.12.28

  optimization of a series of pyrrolopyrimidine inhibitors of interleukin-1 receptor associated kinase 4 (IRAK4) using X-ray crystal structures and structure based design to identify and optimize our scaffold. Compound 28 demonstrated a favorable physicochemical and kinase selectivity profile and was identified as a promising in vivo tool with which to explore the role of IRAK4 inhibition in the treatment of mutant

  本文中，我们报告了使用X射线晶体结构和基于结构的设计来鉴定和优化我们的支架，优化了一系列白介素1受体相关激酶4（IRAK4）的吡咯并嘧啶抑制剂。化合物28表现出良好的理化和激酶选择性，并被认为是一种有前途的体内工具，可利用该工具探索IRAK4抑制作用在突变MYD88 L265P弥漫性大B细胞淋巴瘤（DLBCL）的治疗中的作用。化合物28已显示在体​​外高浓度下具有抑制NF-κB活化和ABC亚型ABC亚型生长的能力，但与低浓度下的BTK抑制剂联用则显示出更大的作用。在体内，化合物28和依鲁替尼的组合在ABC-DLBCL小鼠模型中导致肿瘤消退。